-
Mashup Score: 0
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 13
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization To create an adaptation, translation, or derivative of the original work, for commercial e-pr ints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 11 day(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 1 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 1 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6EBMT, ELN Working Group Publish Updated Guidelines for HSCT in Myelofibrosis | Blood Cancers Today - 2 month(s) ago
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Adding Parsaclisib to Ruxolitinib Improves Myelofibrosis Symptoms and Spleen Volume | Blood Cancers Today - 2 month(s) ago
Adding parsaclisib to ruxolitinib can improve symptoms and spleen volume in patients with myelofibrosis who do not respond optimally to ruxolitinib therapy alone.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
A mouse study suggests that platelet factor 4 (PF4) derived from megakaryocytes, cells that are known to promote inflammation, plays a critical role in the progression of MPNs.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
The phase 3 MANIFEST-2 clinical trial determined that pelabresib plus Jakafi improved survival outcomes and quality of life in patients with #myelofibrosis, explained Dr. John Mascarenhas of @IcahnMountSinai. Read more here: https://t.co/lS2PMrDmpD